Glutathione: oral, IV and topical, and what each has been shown to do

Glutathione is a three-amino-acid peptide your body makes in every cell, and it is the main thing standing between those cells and oxidative damage. As a supplement it is sold three ways: capsules, IV drips and creams. The best trial shows that daily oral glutathione raises body stores by roughly a third over six months. The skin-lightening evidence amounts to a handful of small, short trials with modest effects, and IV glutathione, the form most heavily marketed for skin, has the weakest evidence and, as of September 2026, an active US contamination investigation.

What it is

Glutathione is built from glutamate, cysteine and glycine. The glutamate is joined through an unusual gamma linkage that resists ordinary protein-digesting enzymes, although one enzyme in the gut lining and liver, gamma-glutamyltransferase, does break it apart [1]. Cysteine’s sulphur group is what does the chemical work: it donates electrons to neutralise oxidants and is then recycled. Cells make their own from amino acids, and plasma levels are low by comparison [1]. Low glutathione is found in many chronic illnesses, which is why raising it has been tried for everything from liver disease to Parkinson’s.

In skin, the theory is that glutathione nudges melanin production away from dark eumelanin towards lighter pigment and dampens the enzyme tyrosinase. That comes mostly from lab work [9]; the trials below test whether it matters in people.

Oral glutathione: how much gets in

For years the answer seemed to be almost none. In 1992, seven healthy volunteers took a single 3 g dose and blood glutathione did not rise at all over the next four and a half hours; the authors concluded the gut and liver break it down first [1].

Longer daily use tells a different story. A Penn State trial randomised 54 non-smoking adults to 250 mg or 1,000 mg of oral glutathione a day, or placebo, for six months [2]. At the higher dose, glutathione rose 30–35% in red cells, plasma and lymphocytes and 260% in cells scraped from inside the cheek; the lower dose raised blood levels 17% and red-cell levels 29% [2]. Levels fell back to baseline within a month of stopping. Natural killer cell activity, one measure of immune function, more than doubled at three months on the high dose [2].

Other forms have smaller evidence bases. A one-month pilot of liposomal glutathione in 12 adults, funded by a company that sells it, reported rises of up to 40% in whole blood within two weeks, with no placebo group [3]. A three-week crossover in 20 people with metabolic syndrome, with two co-authors from a French pharmaceutical laboratory, found the under-the-tongue form raised plasma glutathione more than standard capsules [4]. Both are worth knowing about and neither settles which form is best.

The skin-lightening trials

This is where most of the demand comes from, so it is worth being exact.

Oral. In a Bangkok trial, 60 medical students took 500 mg a day or placebo for four weeks [5]. Melanin fell at all six skin sites measured, but beat placebo significantly at only two: the right side of the face and the sun-exposed forearm. The authors themselves wrote that it lightened skin “in a small number of subjects” and that long-term safety was unknown [5]. A follow-up from the same group gave 250 mg a day of reduced or oxidised glutathione, or placebo, to healthy women for 12 weeks; melanin “tended to be lower” than placebo, and some sites showed fewer wrinkles [6].

Topical. In a split-face trial, 30 healthy women aged 30 to 50 applied a 2% oxidised glutathione lotion to one side of the face and placebo to the other for 10 weeks [7]. The treated side had a lower melanin index from early on, significant by 10 weeks (p less than 0.001), plus better moisture and smoothness [7]. Three of the four authors worked for Kyowa Hakko Bio, an ingredient manufacturer, and the trial was run by a contract research firm in the Philippines.

IV. Only one placebo-controlled trial of IV glutathione for skin lightening exists, and it was not published in an indexed journal. A 2025 systematic review reports its result as 6 of 16 people responding on glutathione versus 3 of 16 on placebo, which was not statistically significant [8]. A 2018 review described its design as dubious and its analysis as apparently flawed [9].

Pooled views. A 2019 systematic review found four trials in total and called the evidence “still inconclusive”, with a possible effect on sun-exposed skin only [15]. The 2025 review concluded that oral and topical glutathione give moderate, reversible lightening, and that IV glutathione for this purpose should not be used, given its lack of efficacy and side effects [8].

Reading the skin claims sensibly

Three details in these trials tend to get lost in marketing. First, the measurements come from a melanin meter held against the skin, so a statistically significant drop can be smaller than anything a person would see in a mirror. Second, where effects appeared, they were mostly on sun-exposed areas such as the face and forearm, not on protected skin [5,15]. Third, the effect is reversible: nobody has shown it persists once the supplement stops, and the longest oral trial ran 12 weeks [6].

It also matters who the market is. A 2018 review noted that demand for glutathione injections has been driven by aggressive marketing in populations with darker skin tones, and that several national regulators have issued bans or warnings on injectable use [9]. The evidence gap is widest precisely where the product is most aggressively sold.

Other conditions tested in people

In Parkinson’s disease, where glutathione is depleted early in the brain [11], a pilot trial gave 21 patients 1,400 mg IV three times a week for four weeks or placebo; motor scores did not differ significantly [10]. An intranasal version, tested in 45 patients for three months, improved scores in every group including placebo, and neither dose beat placebo [11]. In fatty liver disease, an open-label study of 34 Japanese patients (29 finished) reported lower ALT, a liver enzyme, after four months of oral glutathione, with no control group [12].

Safety and side effects reported

Oral glutathione has looked well tolerated in trials of up to six months [2,5]. Topical use produced no marked adverse effects in its one trial [7].

Injected glutathione is different. In August 2026 the FDA reported at least 30 patients with adverse reactions after IV glutathione, including fever, chills, dizziness, shock and sepsis-like symptoms, some needing hospital care [13]. The products were made by compounding pharmacies from glutathione labelled as dietary-supplement grade, traced to a single contaminated lot, and the problem was endotoxin, a bacterial toxin [13]. The CDC’s investigation, updated 11 September 2026, counts more than 25 people ill across at least four states, three hospitalised, one needing intensive care for shock and clotting problems [14]. The FDA says it raised similar concerns in 2019 [13]. Reviews of skin-lightening injections have also flagged reports of serious skin reactions, thyroid and kidney problems, and pain, with poor documentation [9].

Legal and regulatory status

In the UK and US, glutathione is sold legally as a food or dietary supplement. It is not approved as a medicine for skin lightening, anti-ageing or general wellness in either country, and IV glutathione in wellness clinics falls outside any licensed indication. Parenteral glutathione is licensed in some countries for narrow uses such as severe liver disorders and preventing chemotherapy nerve damage [9]. Glutathione itself is not on the WADA Prohibited List, although WADA separately limits the volume of IV infusions athletes may receive outside hospital care.

What we still don’t know

• Whether raising glutathione by a third changes any health outcome. The trials measure levels, not disease.
• Whether skin effects last, and what happens to pigment after stopping. The longest skin trial ran 12 weeks.
• Whether liposomal or sublingual forms beat plain capsules in independent, placebo-controlled trials.
• The long-term safety of repeated IV glutathione, even when it is properly manufactured.

Educational content only — not medical advice. Many peptides discussed on HPR are not approved for human use. Talk to a qualified clinician before making any decision about your health.

Free live webinar · Thursday 1 October · 7pm UK time

Join the next webinar: Introduction to Peptides

with Mitch O’Callaghan, ISSCA Peptide Therapist · Founder, Proper Protocols

Save my free placeHPR×Proper Protocols